An eicosanoid-centric view of atherothrombotic risk factors

Cellular and Molecular Life Sciences

Volumn 69, Issue 20, 2012, Pages 3361-3380

  Gleim, Scott ^a   Stitham, Jeremiah ^a   Tang, Wai Ho ^a   Martin, Kathleen A ^a   Hwa, John ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherothrombosis; Diabetes mellitus; Eicosanoids; Hyperlipidemia; Hypertension; Oxidative stress; Platelets; Prostaglandins; Prostanoids

Indexed keywords

20 HYDROXYEICOSATRIENOIC ACID; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; C REACTIVE PROTEIN; CALCIUM; CYCLIC AMP; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; EPOXYEICOSANOID; FAT DROPLET; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; HYDROXYICOSATRIENOIC ACID; ICOSANOID; ICOSAPENTAENOIC ACID; INSULIN; ISOPROSTANE; LEUKOTRIENE; LEUKOTRIENE C4; LEUKOTRIENE D4; LEUKOTRIENE E4; LEUKOTRIENE RECEPTOR; OXIDIZED LOW DENSITY LIPOPROTEIN; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; THROMBOXANE; THROMBOXANE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADIPOCYTE; BLOOD PRESSURE; CALCIUM TRANSPORT; CARDIOVASCULAR RISK; CELL MEMBRANE DEPOLARIZATION; CEREBROVASCULAR ACCIDENT; CHOLESTEROL TRANSPORT; DIABETES MELLITUS; DYSLIPIDEMIA; GENDER; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERPOLARIZATION; HYPERTENSION; INFLAMMATION; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; ISCHEMIC HEART DISEASE; LIPOLYSIS; LOW DRUG DOSE; METABOLIC SYNDROME X; MORBID OBESITY; NONHUMAN; OBESITY; OXIDATIVE STRESS; PROSTAGLANDIN SYNTHESIS; REVIEW; RISK FACTOR; SMOKING; SODIUM RETENTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE DISORDER; THROMBOSIS; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ANIMALS; ATHEROSCLEROSIS; EICOSANOIDS; HUMANS; MICE; RISK FACTORS; THROMBOSIS;

EID: 84867573016     PISSN: 1420682X     EISSN: 14209071     Source Type: Journal    
DOI: 10.1007/s00018-012-0982-9     Document Type: Review

References (315)

1. Roger VL et al (2012) Heart disease and stroke statistics-2012 update: A report from the American Heart Association. Circulation 125(1):e2-e220
2. Ross R (1999) Atherosclerosis-an inflammatory disease. N Engl J Med 340(2):115-126
3. Weber C, Noels H (2011) Atherosclerosis: Current pathogenesis and therapeutic options. Nat Med 17(11):1410-1422
4. Jackson SP (2011) Arterial thrombosis-insidious, unpredictable and deadly. Nat Med 17(11):1423-1436
5. Bird DA et al (1999) Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macrophages can recognize both the modified lipid moieties and the modified protein moieties: Implications with respect to macrophage recognition of apoptotic cells. Proc Nat Acad Sci 96(11):6347-6352
6. Glass CK, Witztum JL (2001) Atherosclerosis: The road ahead. Cell 104(4):503-516
7. Libby P et al (2010) Inflammation in atherosclerosis: Transition from theory to practice. Circ J 74(2):213-220
8. Rocha VZ, Libby P (2009) Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 6(6):399-409
9. Libby P (2002) Inflammation in atherosclerosis. Nature 420(6917):868-874
10. Angiolillo DJ, Ueno M, Goto S (2010) Basic principles of platelet biology and clinical implications. Circ J 74(4):597-607
11. Kaufmann BA et al (2010) Molecular imaging of the initial inflammatory response in atherosclerosis: Implications for early detection of disease. Arterioscler Thromb Vasc Biol 30(1): 54-59
12. Braun OO et al (2008) Primary and secondary capture of platelets onto inflamed femoral artery endothelium is dependent on P-selectin and PSGL-1. Eur J Pharmacol 592(1-3):128-132
13. Furie B, Furie BC (2004) Role of platelet P-selectin and microparticle PSGL-1 in thrombus formation. Trends Mol Med 10(4):171-178
14. Theilmeier G et al (2002) Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia. Blood 99(12):4486-4493
15. Ruggeri ZM (2002) Platelets in atherothrombosis. Nat Med 8(11):1227-1234
16. Gawaz M, Langer H, May AE (2005) Platelets in inflammation and atherogenesis. J Clin Invest 115(12):3378-3384
17. Jackson SP (2007) The growing complexity of platelet aggregation. Blood 109(12):5087-5095
18. Denis CV, Wagner DD (2007) Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler Thromb Vasc Biol 27(4):728-739
19. Varga-Szabo D, Pleines I, Nieswandt B (2008) Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol 28(3):403-412
20. Jennings LK (2009) Mechanisms of platelet activation: Need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost 102(2):248-257
21. Kapoor JR (2008) Platelet activation and atherothrombosis. N Engl J Med 358(15):1638 (author reply 1638-1639)
22. Davi G, Patrono C (2007) Platelet activation and atherothrombosis. N Engl J Med 357(24):2482-2494
23. Yousuf O, Bhatt DL (2011) The evolution of antiplatelet therapy in cardiovascular disease. Nat Rev Cardiol 8(10):547-559
24. Hirsh J (1987) Hyperactive platelets and complications of coronary artery disease. N Engl J Med 316(24):1543-1544
25. Panigrahy D et al (2010) Cytochrome P450-derived eicosanoids: The neglected pathway in cancer. Cancer Metastasis Rev 29(4):723-735
26. Nithipatikom K, Gross GJ (2010) Review article: Epoxyeicosatrienoic acids: Novel mediators of cardioprotection. J Cardiovasc Pharmacol Ther 15(2):112-119
27. Ricciotti E, FitzGerald GA (2011) Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31(5):986-1000
28. Sala A, Folco G, Murphy RC (2010) Transcellular biosynthesis of eicosanoids. Pharmacol Rep 62(3):503-510
29. Rokach J et al (2004) Total synthesis of isoprostanes: Discovery and quantitation in biological systems. Chem Phys Lipids 128(1-2):35-56
30. Janssen LJ (2001) Isoprostanes: An overview and putative roles in pulmonary pathophysiology. Am J Physiol Lung Cell Mol Physiol 280(6):L1067-L1082
31. Coleman RA, Smith WL, Narumiya S (1994) International union of pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46(2):205-229
32. Drazen JM et al (1980) Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. Proc Natl Acad Sci USA 77(7):4354-4358
33. Hasegawa S et al (2010) Functional expression of cysteinyl leukotriene receptors on human platelets. Platelets 21(4): 253-259
34. Nonaka Y, Hiramoto T, Fujita N (2005) Identification of endogenous surrogate ligands for human P2Y12 receptors by in silico and in vitro methods. Biochem Biophys Res Commun 337(1):281-288
35. Node K et al (1999) Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 285 :1276-1279
36. Li N et al (2011) Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease. Congest Heart Fail 17(1):42-46
37. Bellien J et al (2011) Modulation of cytochrome-derived epoxyeicosatrienoic acids pathway: A promising pharmacological approach to prevent endothelial dysfunction in cardiovascular diseases? Pharmacol Ther 131(1):1-17
38. Capdevila JH, Falck JR, Harris RC (2000) Cytochrome P450 and arachidonic acid bioactivation: Molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 41(2):163-181
39. Fleming I et al (2001) Endothelium-derived hyperpolarizing factor synthase (cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 88(1):44-51
40. Viswanathan S et al (2003) Involvement of CYP 2C9 in mediating the proinflammatory effects of linoleic acid in vascular endothelial cells. J Am Coll Nutr 22(6):502-510
41. CDC (2011) Prevalence of coronary heart disease-United States, 2006-2010. Morb Mortal Wkly Rep 60(40):1377-1381
42. Splansky GL et al (2007) The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: Design, recruitment, and initial examination. Am J Epidemiol 165(11):1328-1335
43. Stewart ST, Cutler DM, Rosen AB (2009) Forecasting the effects of obesity and smoking on U.S. life expectancy. N Engl J Med 361(23):2252-2260
44. ADVANCE (2008) Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358(24):2560-2572
45. ACCORD Group (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358(24):2545-2559
46. Duckworth W et al (2009) Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360(2):129-139
47. Cushman WC et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362(17): 1575-1585
48. Zoungas S et al (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363(15):1410-1418
49. Fisher M, Loscalzo J (2011) The perils of combination antithrombotic therapy and potential resolutions. Circulation 123(3):232-235
50. Angiolillo DJ et al (2011) Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: Randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther 89(1):65-74
51. Wilson PW et al (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97(18):1837-1847
52. Wilson PWF, Castelli WP, Kannel WB (1987) Coronary risk prediction in adults (The Framingham Heart Study). Am J Cardiol 59(14):G91-G94
53. Yanes LL, Reckelhoff JF (2011) Postmenopausal hypertension. Am J Hypertens 24(7):740-749
54. Schenck-Gustafsson K et al (2011) EMAS position statement: Managing the menopause in the context of coronary heart disease. Maturitas 68(1):94-97
55. Egan K et al (2004) COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306(5703):1954-1957
56. Turner EC, Kinsella BT (2010) Estrogen increases expression of the human prostacyclin receptor within the vasculature through an ERalpha-dependent mechanism. J Mol Biol 396(3):473-486
57. Ridker PM et al (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352(13):1293-1304
58. Smith DD et al (2010) Increased aortic atherosclerotic plaque development in female apolipoprotein E-null mice is associated with elevated thromboxane A2 and decreased prostacyclin production. J Physiol Pharmacol 61(3):309-316
59. Leslie CA, Gonnerman WA, Cathcart ES (1987) Gender differences in eicosanoid production from macrophages of arthritissusceptible mice. J Immunol 138(2):413-416
60. Zhou Y et al (2005) Gender differences of renal CYP-derived eicosanoid synthesis in rats fed a high-fat diet[ast]. Am J Hypertens 18(4):530-537
61. Ward NC et al (2005) Urinary 20-hydroxyeicosatetraenoic acid excretion is associated with oxidative stress in hypertensive subjects. Free Radical Biol Med 38(8):1032-1036
62. Ward NC et al (2004) Urinary 20-hydroxyeicosatetraenoic acid is associated with endothelial dysfunction in humans. Circulation 110(4):438-443
63. Yanes LL et al (2011) Postmenopausal hypertension: Role of 20-HETE. Am J Physiol Regul Integr Comp Physiol 300(6): R1543-R1548
64. Liang C-J et al (2011) 20-Hydroxyeicosatetraenoic acid inhibits ATP-induced COX-2 expression via peroxisome proliferator activator receptor-a in vascular smooth muscle cells. Br J Pharmacol 163(4):815-825
65. Tunctan B et al (2011) Contribution of vasoactive eicosanoids and nitric oxide production to the effect of selective cyclooxygenase-2 inhibitor, NS-398, on endotoxin-induced hypotension in rats. Blackwell Publishing Ltd, Oxford, pp 877-882
66. Tsai IJ et al (2011) 20-Hydroxyeicosatetraenoic acid synthesis is increased in human neutrophils and platelets by angiotensin II and endothelin-1. Am J Physiol Heart Circ Physiol 300(4): H1194-H1200
67. Lange A et al (1997) 20-Hydroxyeicosatetraenoic acid-induced vasoconstriction and inhibition of potassium current in cerebral vascular smooth muscle is dependent on activation of protein kinase C. J Biol Chem 272(43):27345-27352
68. Gebremedhin D et al (1998) Cat cerebral arterial smooth muscle cells express cytochrome P450 4A2 enzyme and produce the vasoconstrictor 20-HETE which enhances L-type Ca2+ current. J Physiol 507(3):771-781
69. Kiowski W et al (1991) Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor. Circulation 83(2):469-475
70. Nelson MT et al (1990) Calcium channels, potassium channels, and voltage dependence of arterial smooth muscle tone. Am J Physiol Cell Physiol 259(1):C3-C18
71. Egan BM, Zhao Y, Axon RN (2010) US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. J Am Med Assoc 303(20):2043-2050
72. Bibbins-Domingo K et al (2010) Projected effect of dietary salt reductions on future cardiovascular disease. N Engl J Med 362(7):590-599
73. Collaboration APCS (2006) The impact of cardiovascular risk factors on the age-related excess risk of coronary heart disease. Int J Epidemiol 35(4):1025-1033
74. Graessler J et al (2009) Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS One 4(7):e6261
75. Quehenberger O, Dennis EA (2011) The human plasma lipidome. N Engl J Med 365(19):1812-1823
76. Gryglewski RJ (2008) Prostacyclin among prostanoids. Pharmacol Rep 60(1):3-11
77. Torpy JM, Lynm C, Glass RM (2010) Hypertension. J Am Med Assoc 303(20):2098
78. Blaustein MP et al (2011) How NaCl raises blood pressure: A new paradigm for the pathogenesis of salt-dependent hypertension. Am J Physiol Heart Circ Physiol 302:H1031-H1049
79. Beckett NS et al (2008) Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358(18):1887-1898
80. Cooper-DeHoff RM et al (2010) Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. J Am Med Assoc 304(1): 61-68
81. Fisher JP, Paton JFR (2011) The sympathetic nervous system and blood pressure in humans: Implications for hypertension. J Hum Hypertens. doi:10.1038/jhh.2011.66
82. Orlov SN, Tremblay J, Hamet P (1996) cAMP signaling inhibits dihydropyridine-sensitive Ca2+ influx in vascular smooth muscle cells. Hypertension 27(3):774-780
83. Kawabe J, Ushikubi F, Hasebe N (2010) Prostacyclin in vascular diseases. Recent insights and future perspectives. Circ J 74(5): 836-843
84. Stitham J et al (2011) Prostacyclin: An inflammatory paradox. Front Pharmacol 2:24
85. Cheng Y et al (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296(5567):539-541
86. Yu Y et al (2009) Cyclooxygenase-2-dependent prostacyclin formation and blood pressure homeostasis. Circ Res 106(2): 337-345
87. Arehart E et al (2008) Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: Potential implications for cyclooxygenase-2 inhibition. Circ Res 102(8): 986-993
88. Jia Z et al (2006) Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion. Circ Res 99(11):1243-1251
89. Jia Z, Wang H, Yang T (2009) Mice lacking mPGES-1 are resistant to lithium-induced polyuria. Am J Physiol Renal Physiol 297(6):F1689-F1696
90. Woodward DF, Jones RL, Narumiya S (2011) International union of basic and clinical pharmacology. LXXXIII: Classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 63(3):471-538
91. Suzuki J-I et al (2011) Roles of prostaglandin E2 in cardiovascular diseases focus on the potential use of a novel selective EP4 receptor agonist. Int Heart J 52(5):266-269
92. Stock JL et al (2001) The prostaglandin E2 EP1 receptor mediates pain perception and regulates blood pressure. J Clin Invest 107(3):325-331
93. Guan Y et al (2007) Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. J Clin Investig 117(9):2496-2505
94. Ai D et al (2007) Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo. Proc Nat Acad Sci 104(21):9018-9023
95. Campbell WB et al (1996) Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res 78(3):415-423
96. Bellien J, Thuillez C, Joannides R (2008) Contribution of endothelium-derived hyperpolarizing factors to the regulation of vascular tone in humans. Fundam Clin Pharmacol 22(4):363-377
97. Zhao X et al (2003) Salt-sensitive hypertension after exposure to angiotensin is associated with inability to upregulate renal epoxygenases. Hypertension 42(4):775-780
98. Fitzpatrick FA et al (1986) Inhibition of cyclooxygenase activity and platelet aggregation by epoxyeicosatrienoic acids. Influence of stereochemistry. J Biol Chem 261(32):15334-15338
99. Krötz F et al (2004) Membrane potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arteri Thromb Vasc Biol 24(3):595-600
100. Krotz F et al (2004) Membrane-potential-dependent inhibition of platelet adhesion to endothelial cells by epoxyeicosatrienoic acids. Arterioscler Thromb Vasc Biol 24(3):595-600
101. Maier KG, Roman RJ (2001) Cytochrome P450 metabolites of arachidonic acid in the control of renal function. Curr Opin Nephrol Hypertens 10(1):81-87
102. Athirakul K et al (2008) Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB J 22(12):4096-4108
103. Campbell WB et al (2002) 14,15-Dihydroxyeicosatrienoic acid relaxes bovine coronary arteries by activation of KCa channels. Am J Physiol Heart Circ Physiol 282(5):H1656-H1664
104. Imig JD et al (2002) Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension 39(2):690-694
105. Liu Y et al (2005) The antiinflammatory effect of laminar flow: The role of PPARc, epoxyeicosatrienoic acids, and soluble epoxide hydrolase. Proc Nat Acad Sci USA 102(46):16747-16752
106. Behm DJ et al (2009) Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: Identification of a novel mechanism of vasodilation. J Pharmacol Exp Ther 328(1):231-239
107. Yamagishi K et al (2008) Fish, x-3 polyunsaturated fatty acids, and mortality from cardiovascular diseases in a nationwide community-based cohort of Japanese men and women: The JACC (Japan Collaborative Cohort Study for Evaluation of Cancer Risk) study. J Am Coll Cardiol 52(12):988-996
108. De Caterina R (2011) n-3 fatty acids in cardiovascular disease. N Engl J Med 364(25):2439-2450
109. Nakayama M et al (1999) Low dose of eicosapentaenoic acid inhibits the exaggerated growth of vascular smooth muscle cells from spontaneously hypertensive rats through suppression of transforming growth factor-beta. J Hypertens 17(10):1421-1430
110. Serebruany VL et al (2011) Early impact of prescription omega-3 fatty acids on platelet biomarkers in patients with coronary artery disease and hypertriglyceridemia. Cardiology 118(3): 187-194
111. Phang M et al (2012) Acute supplementation with eicosapentaenoic acid reduces platelet microparticle activity in healthy subjects. J Nutr Biochem. doi:10.1016/j.jnutbio.2011.06.006
112. Larsen BT et al (2008) Hydrogen peroxide inhibits cytochrome p450 epoxygenases: Interaction between two endotheliumderived hyperpolarizing factors. Circ Res 102(1):59-67
113. Bauersachs J et al (1996) Nitric oxide attenuates the release of endothelium-derived hyperpolarizing factor. Circulation 94(12):3341-3347
114. Zalba G et al (2001) Oxidative stress in arterial hypertension: Role of NAD(P)H oxidase. Hypertension 38(6):1395-1399
115. Alexander RW (1995) Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: A new perspective. Hypertension 25(2):155-161
116. Weintraub WS et al (1985) Importance of total life consumption of cigarettes as a risk factor for coronary artery disease. Am J Cardiol 55(6):669-672
117. Bazzano LA et al (2003) Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med 138(11):891-897
118. Sokolowska B et al (2010) Influence of leukotriene biosynthesis inhibition on heart rate in patients with atrial fibrillation. Int J Cardiol 145(3):625-626
119. Kawabata K et al (2010) Inhibition of secretory phospholipase A2 activity attenuates acute cardiogenic pulmonary edema induced by isoproterenol infusion in mice after myocardial infarction. J Cardiovasc Pharmacol 56(4):369-378. doi:10.1097/ FJC.0b013e3181ef1aab
120. Mozaffarian D, Wu JHY (2011) Omega-3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events. J Am Coll Cardiol 58(20):2047-2067
121. Sanak M et al (2010) Pharmacological inhibition of leukotriene biosynthesis: Effects on the heart conductance. J Physiol Pharmacol 61(1):53-58
122. Mozes T et al (1991) Sequential release of eicosanoids during endotoxin-induced shock in anesthetized pigs. Prostaglandins Leukot Essent Fatty Acids 42(4):209-216
123. Gesquiere L, Loreau N, Blache D (2000) Role of the cyclic AMP-dependent pathway in free radical-induced cholesterol accumulation in vascular smooth muscle cells. Free Radical Biol Med 29(2):181-190
124. Makheja AN (1992) Atherosclerosis: The eicosanoid connection. Mol Cell Biochem 111(1):137-142
125. O'Brien JJ et al (2007) The platelet as a therapeutic target for treating vascular diseases and the role of eicosanoid and synthetic PPARc ligands. Prostaglandins Other Lipid Mediat 82(1-4):68-76
126. Xie YH et al (2010) Up-regulation of G-protein-coupled receptors for endothelin and thromboxane by lipid-soluble smoke particles in renal artery of rat. Basic Clin Pharmacol Toxicol 107(4):803-812
127. Milara J et al (2010) Cigarette smoke exposure up-regulates endothelin receptor B in human pulmonary artery endothelial cells: Molecular and functional consequences. Br J Pharmacol 161(7):1599-1615
128. Vayssettes-Courchay C et al (2010) Role of thromboxane TP and angiotensin AT1 receptors in lipopolysaccharide-induced arterial dysfunction in the rabbit: An in vivo study. Eur J Pharmacol 634(1-3):113-120
129. Agarwal R (2005) Smoking, oxidative stress and inflammation: Impact on resting energy expenditure in diabetic nephropathy. BMC Nephrol 6:13
130. Taylor A, Bruno R, Traber M (2008) Women and smokers have elevated urinary F(2)-isoprostane metabolites: A novel extraction and LC-MS methodology. Lipids 43(10):925-936
131. Morrow JD et al (1995) Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 332(18):1198-1203
132. Reilly M et al (1996) Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94(1):19-25
133. Collaboration HS (2002) Homocysteine and risk of ischemic heart disease and stroke. J Am Med Assoc 288(16):2015-2022
134. Woo KS et al (1997) Hyperhomocyst(e)inemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 96(8):2542-2544
135. Miller JW et al (1994) Vitamin B-6 deficiency vs folate deficiency: Comparison of responses to methionine loading in rats. Am J Clin Nutr 59(5):1033-1039
136. Di Minno G et al (1993) Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. J Clin Investig 92(3):1400-1406
137. Davi G et al (2001) Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 104(10):1124-1128
138. Durand P, Lussier-Cacan S, Blache D (1997) Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J 11(13):1157-1168
139. Bonaa KH et al (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354(15):1578-1588
140. Lonn E et al (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354(15):1567-1577
141. Csordas A et al (2008) An evaluation of the clinical evidence on the role of inflammation and oxidative stress in smoking-mediated cardiovascular disease. Biomark Insights 3:127-139
142. Barden A et al (2011) The effects of oxidation products of arachidonic acid and n3 fatty acids on vascular and platelet function. Free Radic Res 45(4):469-476
143. Kinsella BT, O'Mahony DJ, Fitzgerald GA (1997) The human thromboxane A2 receptor alpha isoform (TP alpha) functionally couples to the G proteins Gq and G11 in vivo and is activated by the isoprostane 8-epi prostaglandin F2 alpha. J Pharmacol Exp Ther 281(2):957-964
144. Pfister SL, Nithipatikom K, Campbell WB (2011) Role of superoxide and thromboxane receptors in acute angiotensin IIinduced vasoconstriction of rabbit vessels. Am J Physiol Heart Circ Physiol 300(6):H2064-H2071
145. Morrow JD, Roberts LJ 2nd (1996) The isoprostanes. Current knowledge and directions for future research. Biochem Pharmacol 51(1):1-9
146. Csiszar A et al (2002) Oxidative stress-induced isoprostane formation may contribute to aspirin resistance in platelets. Prostaglandins Leukot Essent Fatty Acids 66(5-6):557-558
147. Bousser MG et al (2009) Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: The prevention of cerebrovascular and cardiovascular events of ischemic originwith terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. Cerebrovasc Dis 27(5):509-518
148. Santilli F, Mucci L, Davi G (2010) TP receptor activation and inhibition in atherothrombosis: The paradigm of diabetes mellitus. Intern Emerg Med 6(3):203-212
149. Egan KM et al (2005) Cyclooxygenases, thromboxane, and atherosclerosis: Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111(3):334-342
150. Prediman KS (2003) Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 41(4, Supplement):S15-S22
151. Seet RCS et al (2011) Biomarkers of oxidative damage in cigarette smokers: Which biomarkers might reflect acute versus chronic oxidative stress? Free Radical Biol Med 50(12):1787-1793
152. Nie D et al (2000) Eicosanoid regulation of angiogenesis: Role of endothelial arachidonate 12-lipoxygenase. Blood 95(7):2304-2311
153. Terres W, Becker P, Rosenberg A (1994) Changes in cardiovascular risk profile during the cessation of smoking. Am J Med 97(3):242-249
154. Alberti KGMM et al (2009) Harmonizing the metabolic syndrome. Circulation 120(16):1640-1645
155. The Emerging Risk Factors Collaboration (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 375(9733):2215-2222
156. Reaven GM (2011) Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: Similarities and differences. J Clin Hypertens 13(4):238-243
157. Shoelson SE, Goldfine AB (2009) Getting away from glucose: Fanning the flames of obesity-induced inflammation. Nat Med 15(4):373-374
158. Razani B, Semenkovich CF (2009) Getting away from glucose: Stop sugarcoating diabetes. Nat Med 15(4):372-373
159. Zoungas S et al (2010) Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363(15):1410-1418
160. Osorio J (2010) Diabetes: Severe hypoglycemia associated with risk of vascular events and death. Nat Rev Cardiol 7(12):666
161. Bridges JM et al (1965) An effect of D-glucose on platelet stickiness. Lancet 1(7376):75-77
162. Vinik AI et al (2001) Platelet dysfunction in type 2 diabetes. Diabetes Care 24(8):1476-1485
163. Gross ER et al (2003) Reactive oxygen species modulate coronary wall shear stress and endothelial function during hyperglycemia. Am J Physiol Heart Circ Physiol 284(5):H1552-H1559
164. Shinomiya K et al (2002) A role of oxidative stress-generated eicosanoid in the progression of arteriosclerosis in type 2 diabetes mellitus model rats. Hypertens Res 25(1):91-98
165. Niedowicz D, Daleke D (2005) The role of oxidative stress in diabetic complications. Cell Biochem Biophys 43(2):289-330
166. Davi G et al (1990) Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322(25): 1769-1774
167. Tang WH et al (2011) Glucose and collagen regulate human platelet activity through aldose reductase induction of thromboxane. J Clin Investig 121(11):4462-4476
168. Davi G et al (1999) In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: Effects of improved metabolic control and vitamin E supplementation. Circulation 99(2):224-229
169. Davi G et al (1997) Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group. Am J Respir Crit Care Med 156(6):1794-1799
170. Santilli F, Mucci L, Davi G (2011) TP receptor activation and inhibition in atherothrombosis: The paradigm of diabetes mellitus. Intern Emerg Med 6(3):203-212
171. Santilli F et al (2006) Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. J Am Coll Cardiol 47(2):391-397
172. Levy RL, White PD (1946) Overweight; its prognostic significance in relation to hypertension and cardiovascular-renal diseases. J Am Med Assoc 131:951-953
173. Graziani F et al (2011) Thromboxane production in morbidly obese subjects. Am J Cardiol 107(11):1656-1661
174. Warlow CP et al (1972) Platelet adhesiveness, coagulation, and fibrinolytic activity in obesity. J Clin Pathol 25(6):484-486
175. Jensen G et al (1991) Risk factors for acute myocardial infarction in Copenhagen, II: Smoking, alcohol intake, physical activity, obesity, oral contraception, diabetes, lipids, and blood pressure. Eur Heart J 12(3):298-308
176. Komukai K et al (2011) Impact of body mass index on clinical outcome in patients hospitalized with congestive heart failure. Circ J 76(1):145-151
177. Curtis JP et al (2005) The obesity paradox: Body mass index and outcomes in patients with heart failure. Arch Intern Med 165(1):55-61
178. Barbarroja N et al (2010) The obese healthy paradox: Is inflammation the answer? Biochem J 430(1):141-149
179. Festa A et al (2000) Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 102(1):42-47
180. Lee DC et al (2011) Long-term effects of changes in cardiorespiratory fitness and body mass index on all-cause and cardiovascular disease mortality in men: The aerobics center longitudinal study. Circulation 124(23):2483-2490
181. Nikolaidis MG, Kyparos A, Vrabas IS (2011) F-isoprostane formation, measurement and interpretation: The role of exercise. Prog Lipid Res 50(1):89-103
182. Downing J, Balady GJ (2011) The role of exercise training in heart failure. J Am Coll Cardiol 58(6):561-569
183. Reilly MP et al (1998) Increased formation of distinct F2 isoprostanes in hypercholesterolemia. Circulation 98(25):2822-2828
184. Davi G et al (1992) Increased thromboxane biosynthesis in type IIa hypercholesterolemia. Circulation 85(5):1792-1798
185. Cyrus T, Ding T, Pratico D (2009) Expression of thromboxane synthase, prostacyclin synthase and thromboxane receptor in atherosclerotic lesions: Correlation with plaque composition. Atherosclerosis 208(2):376-381
186. Goldstein JL et al (1985) Receptor-mediated endocytosis: Concepts emerging from the LDL receptor system. Annu Rev Cell Biol 1:1-39
187. Siess W (2006) Platelet interaction with bioactive lipids formed by mild oxidation of low-density lipoprotein. Pathophysiol Haemost Thromb 35(3-4):292-304
188. Ishigaki Y et al (2008) Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis. Circulation 118(1): 75-83
189. Puccetti L et al (2011) Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 214(1):122-128
190. Santos-Gallego C, Giannarelli C, Badimo'n J (2011) Experimental models for the investigation of high-density lipoproteinmediated cholesterol efflux. Curr Atheroscler Rep 13(3):266-276
191. Proudfoot JM et al (2009) HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J Lipid Res 50(4):716-722
192. Waksman R et al (2010) A first-in-man, randomized, placebocontrolled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. J Am Coll Cardiol 55(24):2727-2735
193. Cottin SC, Sanders TA, Hall WL (2011) The differential effects of EPA and DHA on cardiovascular risk factors. Proc Nutr Soc 70(2):215-231
194. Mas E et al (2010) The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: Results from two placebocontrolled interventions. Free Radic Res 44(9):983-990
195. Guillot N et al (2008) Effects of docosahexaenoic acid on some megakaryocytic cell gene expression of some enzymes controlling prostanoid synthesis. Biochem Biophys Res Commun 372(4):924-928
196. Vericel E et al (2003) Pro-and antioxidant activities of docosahexaenoic acid on human blood platelets. J Thromb Haemost 1(3):566-572
197. Dombrowsky H et al (2011) Ingestion of (n-3) fatty acids augments basal and platelet activating factor-induced permeability to dextran in the rat mesenteric vascular bed. J Nutr 141(9): 1635-1642
198. Wada M et al (2007) Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem 282(31): 22254-22266
199. Marcelin G, Chua S Jr (2010) Contributions of adipocyte lipid metabolism to body fat content and implications for the treatment of obesity. Curr Opin Pharmacol 10(5):588-593
200. Enerbäck S (2009) The origins of brown adipose tissue. N Engl J Med 360(19):2021-2023
201. Raclot T et al (1997) Selective release of human adipocyte fatty acids according to molecular structure. Biochem J 324(Pt 3): 911-915
202. Vassaux G et al (1992) Differential response of preadipocytes and adipocytes to prostacyclin and prostaglandin E2: Physiological implications. Endocrinology 131(5):2393-2398
203. Jaworski K et al (2009) AdPLA ablation increases lipolysis and prevents obesity induced by high-fat feeding or leptin deficiency. Nat Med 15(2):159-168
204. Vegiopoulos A et al (2010) Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. Science 328(5982):1158-1161
205. Carmen GY, Víctor SM (2006) Signalling mechanisms regulating lipolysis. Cell Signal 18(4):401-408
206. Fain JN et al (2004) Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 145(5):2273-2282
207. Alexandru N, Popov D, Georgescu A (2011) Platelet dysfunction in vascular pathologies and how can it be treated. Thromb Res 129(2):116-126
208. Zuern CS, Lindemann S Gawaz M (2009) Platelet function and response to aspirin: Gender-specific features and implications for female thrombotic risk and management. Semin Thromb Hemost 35(3):295-306
209. Park B-J et al (2012) The relationship of platelet count, mean platelet volume with metabolic syndrome according to the criteria of the American Association of Clinical Endocrinologists: A focus on gender differences. Platelets 23(1):45-50
210. Hamet P et al (1985) Abnormalities of platelet function in hypertension and diabetes. Hypertension 7(6 Pt 2):II135-II142
211. Kjeldsen SE et al (1991) The epinephrine-blood platelet connection with special reference to essential hypertension. Am Heart J 122(1 Pt 2):330-336
212. Wei AH et al (2009) New insights into the haemostatic function of platelets. Br J Haematol 147(4):415-430
213. Roethig HJ et al (2010) Short term effects of reduced exposure to cigarette smoke on white blood cells, platelets and red blood cells in adult cigarette smokers. Regul Toxicol Pharmacol 57(2-3):333-337
214. Padmavathi P et al (2010) Smoking-induced alterations in platelet membrane fluidity and Na?/K?-ATPase activity in chronic cigarette smokers. J Atheroscler Thromb 17(6):619-627
215. Neubauer H et al (2009) Upregulation of platelet CD40, CD40 ligand (CD40L) and P-Selectin expression in cigarette smokers: A flow cytometry study. Blood Coagul Fibrinolysis 20(8):694-698
216. Vazzana N et al (2012) Diabetes mellitus and thrombosis. Thrombosis Res 129(3):371-377
217. Mylotte D et al (2012) Platelet reactivity in type 2 diabetes mellitus: A comparative analysis with survivors of myocardial infarction and the role of glycaemic control. Platelets. doi: 10.3109/09537104.2011.634932
218. Murakami T et al (2007) Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb Res 119(1):45-53
219. De Pergola G et al (2008) sP-selectin plasma levels in obesity: Association with insulin resistance and related metabolic and prothrombotic factors. Nutr Metab Cardiovasc Dis 18(3):227-232
220. Anfossi G, Russo I, Trovati M (2009) Platelet dysfunction in central obesity. Nutr Metab Cardiovasc Dis 19(6):440-449
221. Trip MD et al (1990) Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 322(22):1549-1554
222. Huo Y et al (2003) Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 9(1):61-67
223. Lievens D et al (2010) Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis. Blood 116(20):4317-4327
224. Giannini S et al (2011) Interaction with damaged vessel wall in vivo in humans induces platelets to express CD40L resulting in endothelial activation with no effect of aspirin intake. Am J Physiol Heart Circ Physiol 300(6):H2072-H2079
225. Dawood BB, Wilde J, Watson SP (2007) Reference curves for aggregation and ATP secretion to aid diagnose of platelet-based bleeding disorders: Effect of inhibition of ADP and thromboxane A2 pathways. Platelets 18(5):329-345
226. Smyth EM (2010) Thromboxane and the thromboxane receptor in cardiovascular disease. Clin Lipidol 5(2):209-219
227. Wilson SJ et al (2009) Activation-dependent stabilization of the human thromboxane receptor: Role of reactive oxygen species. J Lipid Res 50(6):1047-1056
228. Zhang M et al (2008) Thromboxane receptor activates the AMPactivated protein kinase in vascular smooth muscle cells via hydrogen peroxide. Circ Res 102(3):328-337
229. Kobzar G, Mardla V, Samel N (2011) Short-term exposure of platelets to glucose impairs inhibition of platelet aggregation by cyclooxygenase inhibitors. Platelets 22(5):338-344
230. Kobayashi T et al (2004) Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoEdeficient mice. J Clin Invest 114(6):784-794
231. Pakala R, Willerson JT, Benedict CR (1997) Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation. Circulation 96(7):2280-2286
232. Yun DH et al (2009) Thromboxane A(2) modulates migration, proliferation, and differentiation of adipose tissue-derived mesenchymal stem cells. Exp Mol Med 41(1):17-24
233. Daniel TO et al (1999) Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res 59(18):4574-4577
234. Iyu D et al (2010) The role of prostanoid receptors in mediating the effects of PGE(2) on human platelet function. Platelets 21(5):329-342
235. Iyu D et al (2010) PGE1 and PGE2 modify platelet function through different prostanoid receptors. Prostaglandins Other Lipid Mediat 94(1-2):9-16
236. Fabre JE et al (2001) Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation. J Clin Invest 107(5):603-610
237. Smith JP et al (2010) PGE2 decreases reactivity of human platelets by activating EP2 and EP4. Thromb Res 126(1):e23-e29
238. Wang M et al (2006) Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci USA 103(39):14507-14512
239. Philipose S et al (2010) The prostaglandin E2 Receptor EP4 is expressed by human platelets and potently inhibits platelet aggregation and thrombus formation. Arterioscler Thromb Vasc Biol 30(12):2416-2423
240. Kuriyama S et al (2010) Selective activation of the prostaglandin E2 receptor subtype EP2 or EP4 leads to inhibition of platelet aggregation. Thromb Haemost 104(4):796-803
241. Petrucci G et al (2010) Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors. J Pharmacol Exp Ther 336(2):391-402
242. Schober LJ et al (2011) The role of PGE(2) in human atherosclerotic plaque on platelet EP(3) and EP(4) receptor activation and platelet function in whole blood. J Thromb Thrombolysis 32(2):158-166
243. Rolland P et al (1984) Alteration in prostacyclin and prostaglandin E2 production. Correlation with changes in human aortic atherosclerotic disease. Arterioscler Thromb Vasc Biol 4(1):70-78
244. Ridker PM et al (2003) C-Reactive Protein, the metabolic syndrome, and risk of incident cardiovascular events. Circulation 107(3):391-397
245. Pepys MB, Hirschfield GM (2003) C-reactive protein: A critical update. J Clin Investig 111(12):1805-1812
246. Blankenberg S et al (2010) Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: The MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation 121(22):2388-2397
247. Ridker PM et al (2002) Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 347(20):1557-1565
248. Koenig W et al (1999) C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men : Results from the MONICA (monitoring trends and determinants in cardiovascular disease) Augsburg Cohort Study, 1984 to 1992. Circulation 99(2):237-242
249. Freeman DJ et al (2002) C-reactive protein is an independent predictor of risk for the development of diabetes in the West of Scotland Coronary Prevention Study. Diabetes 51(5):1596-1600
250. Eisenhardt SU et al (2009) C-reactive protein: How conformational changes influence inflammatory properties. Cell Cycle 8(23):3885-3892
251. Thompson D, Pepys MB, Wood SP (1999) The physiological structure of human C-reactive protein and its complex with phosphocholine. Structure 7(2):169-177
252. Eisenhardt SU, Habersberger J, Peter K (2009) Monomeric C-reactive protein generation on activated platelets: The missing link between inflammation and atherothrombotic risk. Trends Cardiovasc Med 19(7):232-237
253. Fiedel BA, Simpson RM, Gewurz H (1982) Effects of C-reactive protein (Crp) on platelet function. Ann N Y Acad Sci 389(1):263-273
254. Grad E et al (2009) Aspirin reduces the prothrombotic activity of C-reactive protein. J Thromb Haemost 7(8):1393-1400
255. Gao XR et al (2009) Efficacy of different doses of aspirin in decreasing blood levels of inflammatory markers in patients with cardiovascular metabolic syndrome. J Pharm Pharmacol 61(11):1505-1510
256. Makhoul Z et al (2011) Associations of obesity with triglycerides and C-reactive protein are attenuated in adults with high red blood cell eicosapentaenoic and docosahexaenoic acids. Eur J Clin Nutr 65(7):808-817
257. Peters-Golden M, Henderson WR Jr (2007) Leukotrienes. N Engl J Med 357(18):1841-1854
258. Helgadottir A et al (2004) The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36(3):233-239
259. Mechiche H et al (2004) Characterization of cysteinyl leukotriene receptors on human saphenous veins: Antagonist activity of montelukast and its metabolites. J Cardiovasc Pharmacol 43(1):113-120
260. Vinten-Johansen J (2004) Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 61(3):481-497
261. Carnini C et al (2011) Synthesis of cysteinyl leukotrienes in human endothelial cells: Subcellular localization and autocrine signaling through the CysLT2 receptor. FASEB J 25(10):3519-3528
262. Capra V et al (2003) Involvement of prenylated proteins in calcium signaling induced by LTD4 in differentiated U937 cells. Prostaglandins Other Lipid Mediat 71(3-4):235-251
263. Hui Y et al (2004) Directed vascular expression of human cysteinyl leukotriene 2 receptor modulates endothelial permeability and systemic blood pressure. Circulation 110(21):3360-3366
264. Jiang W et al (2008) Endothelial cysteinyl leukotriene 2 receptor expression mediates myocardial ischemia-reperfusion injury. Am J Pathol 172(3):592-602
265. Yu GL et al (2005) Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose-and time-dependently protects against focal cerebral ischemia in mice. Pharmacology 73(1):31-40
266. Sener G et al (2006) Montelukast protects against renal ischemia/ reperfusion injury in rats. Pharmacol Res 54(1):65-71
267. Back M et al (2005) Leukotriene B4 signaling through NFkappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA 102(48):17501-17506
268. Subbarao K et al (2004) Role of leukotriene B4 receptors in the development of atherosclerosis: Potential mechanisms. Arterioscler Thromb Vasc Biol 24(2):369-375
269. Heller EA et al (2005) Inhibition of atherogenesis in BLT1-deficient mice reveals a role for LTB4 and BLT1 in smooth muscle cell recruitment. Circulation 112(4):578-586
270. Bäck M (2009) Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther 23(1):41-48
271. Aiello RJ et al (2002) Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol 22(3):443-449
272. Kaetsu Y et al (2007) Role of cysteinyl leukotrienes in the proliferation and the migration of murine vascular smooth muscle cells in vivo and in vitro. Cardiovasc Res 76(1):160-166
273. Jawien J et al (2008) The effect of montelukast on atherogenesis in apoE/LDLR-double knockout mice. J Physiol Pharmacol 59(3):633-639
274. Mueller CF et al (2008) Multidrug resistance protein-1 affects oxidative stress, endothelial dysfunction, and atherogenesis via leukotriene C4 export. Circulation 117(22):2912-2918
275. Opper C et al (1995) Increased number of high sensitive platelets in hypercholesterolemia, cardiovascular diseases, and after incubation with cholesterol. Atherosclerosis 113(2):211-217
276. Matsuoka T et al (2000) Prostaglandin D2 as a mediator of allergic asthma. Science 287(5460):2013-2017
277. Eguchi Y et al (1997) Expression of lipocalin-type prostaglandin D synthase (beta-trace) in human heart and its accumulation in the coronary circulation of angina patients. Proc Natl Acad Sci USA 94(26):14689-14694
278. Taba Y et al (2000) Fluid shear stress induces lipocalin-type prostaglandin D(2) synthase expression in vascular endothelial cells. Circ Res 86(9):967-973
279. Hirawa N et al (2002) Lipocalin-type prostaglandin d synthase in essential hypertension. Hypertension 39(2 Pt 2):449-454
280. Inoue T et al (2008) Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease. Atherosclerosis 201(2):385-391
281. Miwa Y et al (2008) Association of serum lipocalin-type prostaglandin D synthase levels with subclinical atherosclerosis in untreated asymptomatic subjects. Hypertens Res 31(10): 1931-1939
282. Sawyer N et al (2002) Molecular pharmacology of the human prostaglandin D2 receptor, CRTH2. Br J Pharmacol 137(8): 1163-1172
283. Bohm E et al (2004) 11-Dehydro-thromboxane B2, a stable thromboxane metabolite, is a full agonist of chemoattractant receptor-homologous molecule expressed on TH2 cells (CRTH2) in human eosinophils and basophils. J Biol Chem 279(9):7663-7670
284. Murray JJ et al (1986) Release of prostaglandin D2 into human airways during acute antigen challenge. N Engl J Med 315(13):800-804
285. Tsukada T et al (1986) Immunocytochemical analysis of cellular components in atherosclerotic lesions. Use of monoclonal antibodies with the Watanabe and fat-fed rabbit. Arteriosclerosis 6(6):601-613
286. Nagoshi H et al (1998) Prostaglandin D2 inhibits inducible nitric oxide synthase expression in rat vascular smooth muscle cells. Circ Res 82(2):204-209
287. Tokudome S et al (2009) Glucocorticoid protects rodent hearts from ischemia/reperfusion injury by activating lipocalin-type prostaglandin D synthase-derived PGD2 biosynthesis. J Clin Invest 119(6):1477-1488
288. Baigent C et al (1998) ISIS-2: 10-year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither. BMJ 316(7141):1337
289. Juni P et al (2004) Risk of cardiovascular events and rofecoxib: Cumulative meta-analysis. Lancet 364(9450):2021-2029
290. Kobayashi T et al (2004) Roles of thromboxane A2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Investig 114(6):784-794
291. Offermanns S (2006) Activation of platelet function through G protein-coupled receptors. Circ Res 99(12):1293-1304
292. Poredos P, Jezovnik MK (2011) Dyslipidemia, statins, and venous thromboembolism. Semin Thromb Hemost 37(8):897-902
293. Raychowdhury MK et al (1994) Alternative splicing produces a divergent cytoplasmic tail in the human endothelial thromboxane A2 receptor. J Biol Chem 269(30):19256-19261
294. Hirata T et al (1996) Two thromboxane A2 receptor isoforms in human platelets. Opposite coupling to adenylyl cyclase with different sensitivity to Arg60 to Leu mutation. J Clin Invest 97(4):949-956
295. Parent JL et al (1999) Internalization of the TXA2 receptor alpha and beta isoforms. Role of the differentially spliced COOH terminus in agonist-promoted receptor internalization. J Biol Chem 274(13):8941-8948
296. Wikström K et al (2008) Differential regulation of RhoA-mediated signaling by the TP[alpha] and TP[beta] isoforms of the human thromboxane A2 receptor: Independent modulation of TP[alpha] signaling by prostacyclin and nitric oxide. Cell Signal 20(8):1497-1512
297. Miggin SM, Kinsella BT (2002) Regulation of extracellular signal-regulated kinase cascades by alpha-and beta-isoforms of the human thromboxane A2 receptor. Mol Pharmacol 61(4):817-831
298. An S et al (1994) Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry 33(48):14496-14502
299. Liang Y et al (2008) Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br J Pharmacol 154(5):1079-1093
300. Wilson SJ et al (2004) Dimerization of the human receptors for prostacyclin and thromboxane facilitates thromboxane receptormediated cAMP generation. J Biol Chem 279(51):53036-53047
301. Wilson SJ et al (2007) Regulation of thromboxane receptor trafficking through the prostacyclin receptor in vascular smooth muscle cells-role of receptor heterodimerization. Arterioscler Thromb Vasc Biol 27(2):290-296
302. Ibrahim S et al (2010) Dominant negative actions of human prostacyclin receptor variant through dimerization: Implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 30(9):1802-1809
303. Wilson SJ et al (2007) Heterodimerization of the alpha and beta isoforms of the human thromboxane receptor enhances isoprostane signaling. Biochem Biophys Res Commun 352(2): 397-403
304. Parhamifar L et al (2010) Ligand-induced tyrosine phosphorylation of cysteinyl leukotriene receptor 1 triggers internalization and signaling in intestinal epithelial cells. PLoS One 5(12): E14439
305. Maekawa A et al (2009) GPR17 is a negative regulator of the cysteinyl leukotriene 1 receptor response to leukotriene D4. Proc Natl Acad Sci USA 106(28):11685-11690
306. Maekawa A et al (2010) GPR17 regulates immune pulmonary inflammation induced by house dust mites. J Immunol 185(3): 1846-1854
307. Patrignani P et al (2008) Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: A clinical biomarker study. Pharmacogenet Genomics 18(7):611-620
308. Ibrahim S et al (2010) Dominant negative actions of human prostacyclin receptor variant through dimerization: Implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 30(9):1802-1809
309. Stitham J, Stojanovic A, Hwa J (2002) Impaired receptor binding and activation associated with a human prostacyclin receptor polymorphism. J Biol Chem 277(18):15439-15444
310. Stitham J et al (2011) Comprehensive biochemical analysis of rare prostacyclin receptor variants study of association of signaling with coronary artery obstruction. J Biol Chem 286(9): 7060-7069
311. Stitham J et al (2010) Comprehensive biochemical analysis of rare prostacyclin receptor variants: Study of association of signaling with coronary artery obstruction. J Biol Chem 286(9): 7060-7069
312. Mumford AD et al (2010) A novel thromboxane A2 receptor D304N variant that abrogates ligand binding in a patient with a bleeding diathesis. Blood 115(2):363-369
313. Thompson MD et al (2006) A functional G300S variant of the cysteinyl leukotriene 1 receptor is associated with atopy in a Tristan da Cunha isolate. Pharmacogenet Genomics 17(7): 539-549
314. Pillai SG et al (2004) A coding polymorphism in the CYSLT2 receptor with reduced affinity to LTD4 is associated with asthma. Pharmacogenetics 14(9):627-633
315. Thompson MD et al (2003) A cysteinyl leukotriene 2 receptor variant is associated with atopy in the population of Tristan da Cunha. Pharmacogenetics 13(10):641-649